Collects donor plasma, refines it into blood products, and delivers them to Chinese hospitals — all inside one company.
At a glance
- Depends onMidstream position: 3 outgoing, 3 incoming connections
- Scale
Collects donor plasma, refines it into blood products, and delivers them to Chinese hospitals — all inside one company.
What this company is and how it runs — written from structure, not news.
Hualan Biological Engineering collects donor plasma through its own NMPA-licensed apheresis centers, separates it into albumin, immunoglobulins, and clotting factors at its own fractionation facilities, and ships the finished products to Chinese hospitals only after each batch clears a mandatory NMPA release certification — so no revenue arrives until every step in that chain is complete. Because NMPA quotas cap how many collection centers can be licensed and restrict where new ones may open, the amount of plasma entering the fractionation process cannot be increased simply by spending more money on equipment, making the licensed donor network the true ceiling on the business. A competitor cannot get around this by building a fractionation plant, because there is no open market for Chinese licensed plasma — the donor supply flows only through centers the NMPA has already approved, most of which Hualan owns. The same integration that keeps rivals out also concentrates the risk: if the NMPA restricts approved donor regions or shuts down collection centers after a contamination event, the fractionation facilities downstream go idle regardless of how much processing capacity sits behind them.
How does this company make money?
The company earns money by selling vaccines to government vaccination programs and hospitals on a per-unit basis. It also sells albumin, immunoglobulins, and clotting factors to hospital blood banks and specialty care centers under volume-based contracts, where the price and quantity are agreed in advance.
What makes this company hard to replace?
Switching to a different supplier is slow and expensive for several reasons. Moving an NMPA biologics registration from one manufacturer to another requires extensive clinical bridging studies — essentially re-proving the product works, which takes years. Hospitals sign multi-year procurement contracts for critical blood products, so they are locked in by agreement even if they wanted to change. Physicians treating rare diseases also build specific familiarity with particular immunoglobulin formulations, making them reluctant to substitute a different product for their patients.
What limits this company?
The NMPA sets strict limits on how many plasma collection centers can operate and where new ones can be licensed. That cap on licensed donor plasma is the ceiling on everything downstream. Buying more fractionation equipment does nothing if there is no additional approved plasma to process — the licensed donor pool, not the machinery, is what determines how much product can be made.
What does this company depend on?
The company cannot operate without five things: NMPA manufacturing licenses that permit biologics production in China, donor plasma collected through NMPA-licensed apheresis centers, cold-chain logistics infrastructure to keep that plasma viable in transit, fractionation equipment to separate the plasma into finished proteins, and NMPA batch release approvals for every single product lot before it can ship.
Who depends on this company?
Chinese hospitals rely on this company's albumin supply for critically ill patients — a shortage would hit intensive care wards directly. China CDC depends on domestically produced vaccines for national vaccination programs. Hemophilia patients who need clotting factor concentrates would have to turn to imported alternatives, which are harder to access and more expensive, if this company's supply stopped.
How does this company scale?
Vaccine production can grow by adding fermentation tanks and fill-finish lines that repeat a well-understood process — that part scales relatively cheaply. Plasma fractionation cannot follow the same path. Because the NMPA caps how much licensed donor plasma can be collected and restricts where new collection centers can open, the plasma supply stays the fixed ceiling even as fractionation capacity expands.
What external forces can significantly affect this company?
Chinese regulatory policy actively favors domestic biologics producers over foreign imports, which protects the company but also means its entire business sits inside one regulatory relationship. An aging Chinese population is pushing up demand for immunoglobulin and albumin products faster than supply can grow. U.S.-China trade tensions create friction around access to Western biologics technologies that the company may need for development or manufacturing upgrades.
Where is this company structurally vulnerable?
If the NMPA changes its collection center licensing rules, shrinks the approved donor regions, or shuts down collection centers after a contamination event, the supply of licensed plasma drops. When that first link breaks, every fractionation facility downstream sits idle — no amount of processing capacity can compensate for having nothing legal to process.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Screen for this company's dividend patterns
Find other companies where the same dividend readings fire.
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company return capital?
Three observations co-occur: dividend payments are large relative to net income (high payout ratio), free cash flow has been positive each of the last three years, and the industry-benchmarked equity ratio is elevated. The high payout ratio happens alongside multi-year FCF positivity and equity-heavy capital structure.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
4 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Three observations co-occur: long-term debt decreased year-over-year in each of the last four fiscal years, total cash at MRQ is at least equal to total debt, and the industry-benchmarked equity ratio is in its elevated range. The configuration describes past LT-debt reduction consistency alongside cash-vs-debt position and equity-heavy capital structure.
Three observations have aligned: retained earnings are a substantial share of total assets, the equity-to-assets ratio is elevated, and current-period dividend payments are a high share of net income (the dividend-payout-intensity observation scores in the upper portion of its 0–100% mapped range).
How is this stock valued?
Retained earnings are a large share of total assets; net income was positive in each of the last 5 fiscal years; shareholders' equity is in the upper part of its industry's equity-to-assets range.
Three observations co-occur: price is several standard deviations below its one-year mean, the company has reported positive net income every year for three years, and the equity ratio is in the elevated industry-benchmarked range. The configuration describes a depressed-price, profitable, equity-funded profile.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph